Latest Research Reports

Immuno-Oncology drugs lead Japanese clinical trials, 2012-2016

Immuno-Oncology drugs lead Japanese clinical trials, 2012-2016

PAH registries may underestimate patient size by as much as sevenfold

PAH registries may underestimate patient size by as much as sevenfold

Pregabalin: the top drug for pain over the last ten years

Pregabalin: the top drug for pain over the last ten years

Alzheimer’s disease and ageing populations

Alzheimer’s disease and ageing populations

Bispecific antibodies and CAR-T cells: A comparison of historical trial numbers and patient recruitment

Bispecific antibodies and CAR-T cells: A comparison of historical trial numbers and patient recruitment

US Sees High Rates of Ovarian Cancer Diagnosed at Stage IV

US Sees High Rates of Ovarian Cancer Diagnosed at Stage IV

Type 2 Diabetes Leads Indications in Russian Clinical Trials, 2012-2016

Type 2 Diabetes Leads Indications in Russian Clinical Trials, 2012-2016

C. difficile pipeline vaccines could offer an alternative to antibiotics

The incidence of Clostridium difficile has increased significantly over the last two decades, due in part to the emergence of new, hyper-virulent strains. In recent years it has surpassed MRSA...

C. difficile pipeline vaccines could offer an alternative to antibiotics

Novavax driving to achieve significant market presence in respiratory complications market

Novavax driving to achieve significant market presence in respiratory complications market

Development of PARP inhibitors for ovarian and breast cancer is equally extensive

A large number of clinical trials evaluating inhibitors of the enzyme poly ADP ribose polymerase (PARP) in breast and ovarian cancers are either ongoing or completed....

Development of PARP inhibitors for ovarian and breast cancer is equally extensive

Amgen and Cytokinetics: moving forward with chronic heart failure therapy

In December, Amgen and Cytokinetics announced that they will be moving forward with their novel chronic heart failure (HF) therapy omecamtiv mecarbil (OM) with the launch of their Phase III...

Amgen and Cytokinetics: moving forward with chronic heart failure therapy